Teva Pharmaceutical Industries Limited (NYSE:TEVA) Shares Sold by D Orazio & Associates Inc.

D Orazio & Associates Inc. trimmed its holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 9.4% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 9,989 shares of the company’s stock after selling 1,034 shares during the quarter. D Orazio & Associates Inc.’s holdings in Teva Pharmaceutical Industries were worth $220,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently made changes to their positions in TEVA. AQR Capital Management LLC acquired a new stake in shares of Teva Pharmaceutical Industries during the second quarter worth $262,000. Cetera Investment Advisers raised its holdings in Teva Pharmaceutical Industries by 83.9% during the 2nd quarter. Cetera Investment Advisers now owns 60,868 shares of the company’s stock worth $989,000 after buying an additional 27,765 shares during the period. Sanctuary Advisors LLC purchased a new stake in Teva Pharmaceutical Industries during the second quarter valued at about $560,000. GAMMA Investing LLC boosted its holdings in shares of Teva Pharmaceutical Industries by 52.3% in the third quarter. GAMMA Investing LLC now owns 5,161 shares of the company’s stock worth $93,000 after buying an additional 1,773 shares during the period. Finally, UMB Bank n.a. increased its position in shares of Teva Pharmaceutical Industries by 555.6% in the third quarter. UMB Bank n.a. now owns 2,439 shares of the company’s stock worth $44,000 after acquiring an additional 2,067 shares in the last quarter. Institutional investors own 54.05% of the company’s stock.

Insiders Place Their Bets

In other Teva Pharmaceutical Industries news, Director Roberto Mignone sold 286,000 shares of the business’s stock in a transaction on Friday, December 20th. The shares were sold at an average price of $22.01, for a total transaction of $6,294,860.00. Following the completion of the transaction, the director now owns 695,000 shares of the company’s stock, valued at $15,296,950. The trade was a 29.15 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Christine Fox sold 19,388 shares of the company’s stock in a transaction dated Wednesday, November 20th. The shares were sold at an average price of $16.87, for a total transaction of $327,075.56. Following the sale, the executive vice president now owns 44,104 shares of the company’s stock, valued at $744,034.48. This trade represents a 30.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 0.55% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts recently commented on the stock. Piper Sandler raised their price objective on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an “overweight” rating in a research note on Friday, January 17th. StockNews.com cut Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, December 18th. UBS Group reduced their price objective on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating for the company in a research note on Thursday, January 30th. JPMorgan Chase & Co. raised their price objective on Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the stock a “neutral” rating in a research report on Monday, October 21st. Finally, Barclays dropped their target price on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating on the stock in a report on Thursday, January 30th. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $23.57.

Teva Pharmaceutical Industries Trading Down 2.6 %

NYSE:TEVA opened at $16.84 on Friday. The stock’s 50 day moving average price is $20.05 and its 200 day moving average price is $18.50. The company has a debt-to-equity ratio of 2.97, a quick ratio of 0.61 and a current ratio of 0.98. Teva Pharmaceutical Industries Limited has a 52 week low of $11.83 and a 52 week high of $22.80.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its quarterly earnings results on Wednesday, January 29th. The company reported $0.70 EPS for the quarter, topping the consensus estimate of $0.69 by $0.01. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. On average, analysts forecast that Teva Pharmaceutical Industries Limited will post 2.62 earnings per share for the current fiscal year.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.